Novartis Pharma (Canadian and European rights for Emselex/Enablex) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novartis Pharma (Canadian and European rights for Emselex/Enablex) General Information

Description

Canadian and European rights for a prescription medicine product. The regional rights comprise of rights to manufacture, market and sell the branded prescription medicine product Emselex and Enablex (darifenacin) extended release tablets. Darifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Canada
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Medical Supplies
Corporate Office
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis Pharma (Canadian and European rights for Emselex/Enablex) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis Pharma (Canadian and European rights for Emselex/Enablex)‘s full profile, request access.

Request a free trial

Novartis Pharma (Canadian and European rights for Emselex/Enablex) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis Pharma (Canadian and European rights for Emselex/Enablex)‘s full profile, request access.

Request a free trial

Novartis Pharma (Canadian and European rights for Emselex/Enablex) FAQs

  • Where is Novartis Pharma (Canadian and European rights for Emselex/Enablex) headquartered?

    Novartis Pharma (Canadian and European rights for Emselex/Enablex) is headquartered in Canada.

  • What industry is Novartis Pharma (Canadian and European rights for Emselex/Enablex) in?

    Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s primary industry is Buildings and Property.

  • Is Novartis Pharma (Canadian and European rights for Emselex/Enablex) a private or public company?

    Novartis Pharma (Canadian and European rights for Emselex/Enablex) is a Private company.

  • What is Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s current revenue?

    The current revenue for Novartis Pharma (Canadian and European rights for Emselex/Enablex) is .

  • Who are Novartis Pharma (Canadian and European rights for Emselex/Enablex)’s investors?

    Novartis Pharma has invested in Novartis Pharma (Canadian and European rights for Emselex/Enablex).

  • When was Novartis Pharma (Canadian and European rights for Emselex/Enablex) acquired?

    Novartis Pharma (Canadian and European rights for Emselex/Enablex) was acquired on 11-Jul-2012.

  • Who acquired Novartis Pharma (Canadian and European rights for Emselex/Enablex)?

    Novartis Pharma (Canadian and European rights for Emselex/Enablex) was acquired by Merus Labs International.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process